254435-95-5
254435-95-5 结构式
基本信息
Debio-025
Trofinetide
alisporivir
Alisporivir (Debio-025)
alisporivir /DB025/DB-025
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-12559 | 254435-95-5 Alisporivir | 254435-95-5 | 1mg | 7000元 |
| 2023/03/20 | HY-16757 | 254435-95-5 Trofinetide | 254435-95-5 | 1mg | 1100元 |
| 2023/03/20 | HY-16757 | 254435-95-5 Trofinetide | 254435-95-5 | 10mM * 1mLin Water | 2289元 |
常见问题列表
DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication. Alisporivir (Debio-025) represents the prototype of a new class of non-immunosuppressive cyclophilin inhibitors. Alisporivir prevents HCV protein-mediated collapse of the respiration-driven mitochondrial membrane potential. Alisporivir prevents HCV protein-mediated mitochondrial dysfunction outside the context of apoptosis, calcium overload, production of ROS, dysfunction. In cell culture models, low-micromolar doses of alisporivir block SARS-CoV and MERS-CoV replication. Combination treatment with Alisporivir and ICN-1229 increases the anti-MERS-CoV activity in cell culture. Alisporivir pretreatment stimulates antigen presentation by hepatoma target cells, leading to enhancement of antigen-specific CD8+ T cell activation by 40%. Alisporivir induces an increase of MHC-I and beta-2 microglobulin on the surface of several cell lines.
Combination treatment with Alisporivir and ICN-1229 does not protect against SARS-CoV infection in a mouse model.